Abstract
Glycogen storage disease type II (GSD II) is an autosomal recessive myopathy. Early and late-onset phenotypes are distinguished – infantile, juvenile and adult. Three mutations in the acid α-glucosidase gene are common in the Dutch patient population: IVS1(-13T→G), 525delT and delexon18 63% of Dutch GSD II patients carry one or two of these mutations, and the genotype–phenotype correlation is known. To determine the frequency of GSD II, we have screened an unselected sample of neonates for the occurrence of these three mutations. Based on the calculated carrier frequencies, the predicted frequency of the disease is 1 in 40 000 divided by 1 in 138 000 for infantile GSD II and 1 in 57 000 for adult GSD II. This is about two to four times higher than previously suggested, which is a reason to become more familiar with the presentation of GSD II in its different clinical forms and to adjust the risk assessment for genetic counselling.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ausems, M., Verbiest, J., Hermans, M. et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 7, 713–716 (1999). https://doi.org/10.1038/sj.ejhg.5200367
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ejhg.5200367
Keywords
This article is cited by
-
Global carrier frequency and predicted genetic prevalence of patients with pathogenic sequence variants in autosomal recessive genetic neuromuscular diseases
Scientific Reports (2024)
-
Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview
Current Treatment Options in Neurology (2022)
-
Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective
Orphanet Journal of Rare Diseases (2021)
-
Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy
Orphanet Journal of Rare Diseases (2021)
-
Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease
Communications Biology (2021)